Skip to content

Diaphragmatic Breathing Exercises for Post-COVID-19 Diaphragmatic Dysfunction (DD)

Diaphragmatic Breathing Exercises for Post-COVID-19 Diaphragmatic Dysfunction (DD)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06330376
Enrollment
16
Registered
2024-03-26
Start date
2024-03-01
Completion date
2025-08-15
Last updated
2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Acute Sequelae of COVID-19

Brief summary

Diaphragm is the principal muscle of inspiration. Diaphragmatic dysfunction is seen in many conditions including following intubation, lung disease, prolonged ventilation, neuromuscular disease, phrenic nerve injury. The possible mechanisms of diaphragmatic dysfunction in patients with COVID19 are critical illness myopathy, ventilator-induced diaphragm dysfunction, iatrogenic phrenic nerve injury particularly secondary to line placement, post-infectious inflammatory neuropathy of the phrenic nerve, or possibly direct neuromuscular involvement of the SARS- CoV-2 virus given expression of the angiotensin- converting enzyme 2 (ACE2) receptor in the peripheral nervous system and skeletal muscle. The use of diaphragmatic ultrasound has been widely used to assess diaphragmatic function is well known in patients following prolonged mechanical ventilation. Prolonged mechanical ventilation leads to contractile dysfunction of respiratory muscles, in particular the diaphragm, causing a so-called ventilator-induced diaphragm dysfunction. The latter is defined as a loss of diaphragm force-generating capacity specifically related to the use of mechanical ventilation. However, the use of diaphragmatic Ultrasound to assess its function in Long COVID patients has not been noted and is a gap in the work up of these patients. The purpose of this study is to address Diaphragmatic Dysfunctional (DD) breathing seen in patients with Post-Acute Sequelae of COVID-19 (PASC), which results in shortness of breath/chest tightness and subsequent fatigue. Targeting shortness of breath and subsequent fatigue as a central symptom of PASC will alleviate long term sequelae for the patients with PASC. DD will be addressed by a unique intervention of physical therapy. The goal of this prospective randomized clinical study will be to evaluate the comparative treatment effect of DB on markers, specifically fatigue, dyspnea, 6 min walk test, depression/anxiety, and quality of life (QoL).

Interventions

OTHERUsual care of traditional treatment

Usual care of traditional treatment which is PT and/or OT when indicated Followed by Pulmonary rehabilitation when indicated

OTHERSpecific DB program/Diaphragmatic manipulation program

12 weeks of 2 sessions/week: one session will be remote and one in-person

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

prospective randomized clinical study with 2 arms

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female age 18 and above * PCR or home kit positive 4 weeks prior to the development of the PASC symptoms * new diagnosis of PASC (defined as new-onset symptoms of fatigue, shortness of breath, chest tightness or persistence of symptoms 4 weeks following a positive PCR test for COVID-19) * patients did not need hospitalization of 5 days or more and did not need ICU admission via chart review or history taking. * nose breathers as reported by patient at the time of screening by history taking * symptoms should include shortness of breath/chest tightness/fatigue

Exclusion criteria

* pre-existing lung disease such as COPD, IPF, Asthma, Exercise induced Asthma, Lung cancer, or history of Lung transplant * history of current smoking and pack years of 10 * history of coronary artery disease * general anxiety disorder without changes in medication and dosage for treatment in the last 4 weeks. * unable to have full range of motion of the shoulders * stable dose of antidepressants prior to covid-19 infection * Pregnant women/fetuses/neonates via self-report. * non-English speakers * patients with previously diagnosed severe cognitive deficits such as dementia, developmental defects, those with acute medical conditions, psychiatric disorders such as schizophrenia, mania, and psychosis, neurologic disorders such as stroke, Parkinson's disease and Multiple sclerosis * unable to read * Individual or group with a serious health condition for which there are no satisfactory standard treatments

Design outcomes

Primary

MeasureTime frameDescription
6-minute walk test (6MWT)6 monthsIt is a simple test that requires no specialized equipment or advanced training for physicians and assesses the submaximal level of functional capacity of an individual while walking on a flat, hard surface in a period of 6 min. It is used to assess the response to a medical therapy, and in cardiac/pulmonary rehabilitation.

Secondary

MeasureTime frameDescription
GAD7: Generalized anxiety disorder 7-item6 monthsmeasures of depression, anxiety, and physical/mental/and social health, respectively, and will serve as covariates in our analysis.
PROMIS score: Patient-Reported Outcomes Measurement Information System6 monthsis a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. It can be used with the general population and with individuals living with chronic conditions. Administration of these scales is a standard of care in our post-COVID clinic.
QoL scale: Quality of life scale6 monthsmeasures of depression, anxiety, and physical/mental/and social health, respectively, and will serve as covariates in our analysis.
PHQ9: Patient health questionnaire 96 monthsmeasures of depression, anxiety, and physical/mental/and social health, respectively, and will serve as covariates in our analysis.
Modified Borg dyspnea scale6 monthsThe Modified Borg Dyspnea Scale (MBS) is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered during six-minute walk testing (6MWT).
RR; respiratory rate with 6 min walk test6 months
PR: pulse rate with 6 min walk test6 months
FACIT fatigue scale 's Fatigue score6 monthsFunctional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (FACIT) FACIT fatigue scale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued) 18 The FACIT Fatigue Scale is one of many different FACIT scales that are part of a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness referred to as The FACIT Measurement System.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026